{"id":9718,"date":"2026-09-08T10:16:56","date_gmt":"2026-09-08T14:16:56","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-provides-september-2026-business-updates\/"},"modified":"2026-10-29T17:45:19","modified_gmt":"2026-10-29T16:45:19","slug":"gensight-biologics-provides-september-2026-business-updates","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/","title":{"rendered":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 8 septembre 2026, 7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui un point sur son activit\u00e9 au cours de l\u2019\u00e9t\u00e9 2026 et confirme la date de publication de ses comptes semestriels 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Point sur la fabrication<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La production du lot d\u2019ing\u00e9nierie (\u00ab engineering run \u00bb), destin\u00e9 \u00e0 confirmer le succ\u00e8s du transfert du proc\u00e9d\u00e9 de fabrication de GS010\/LUMEVOQ<sup>\u00ae<\/sup> chez Catalent, s\u2019est d\u00e9roul\u00e9e comme pr\u00e9vu. Le titre en g\u00e9nomes viraux (vg) de la substance active, qui mesure la concentration du g\u00e8ne th\u00e9rapeutique, est conforme aux sp\u00e9cifications cibles. Le titre en vg obtenu dans ce lot ainsi que dans les lots de d\u00e9veloppement du proc\u00e9d\u00e9, de m\u00eame que la reproductibilit\u00e9 du titre en vg lors de la phase en amont du proc\u00e9d\u00e9, indiquent que le proc\u00e9d\u00e9 transf\u00e9r\u00e9 chez Catalent permettra d\u2019obtenir des rendements reproductibles. L\u2019ensemble des r\u00e9sultats des tests r\u00e9alis\u00e9s sur la substance active, qui d\u00e9montreront le succ\u00e8s du transfert de la phase en amont du proc\u00e9d\u00e9, est attendu \u00e0 la fin de l\u2019\u00e9t\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les r\u00e9sultats obtenus \u00e0 ce jour ont d\u00e9j\u00e0 permis de lancer les activit\u00e9s pr\u00e9paratoires \u00e0 la fabrication du lot GMP qui servira \u00e0 approvisionner les programmes d\u2019acc\u00e8s d\u00e9rogatoires de la Soci\u00e9t\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Point sur les activit\u00e9s cliniques<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019ensemble des patients restant \u00e0 inclure dans l\u2019\u00e9tude de dose REVISE, men\u00e9e en France \u00e0 la demande de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM), ont \u00e9t\u00e9 identifi\u00e9s. Le dernier traitement est pr\u00e9vu en d\u00e9cembre 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En France, la s\u00e9lection des patients a repris au titre du programme d\u2019acc\u00e8s compassionnel (AAC), apr\u00e8s leurs suspensions durant la pause estivale. \u00c0 ce jour, certains patients ont d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En juillet, un premier patient a \u00e9t\u00e9 trait\u00e9 au titre du programme d\u2019acc\u00e8s pr\u00e9coce nominatif Isra\u00e9lien.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u2019autres traitements devraient avoir lieu dans d\u2019autres pays d\u2019ici la fin de l\u2019ann\u00e9e 2026, dans le cadre de programmes d\u2019acc\u00e8s d\u00e9rogatoires payants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Point financier<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dans la cadre de la reprise du programme AAC, les revenus associ\u00e9s \u00e0 ces traitements ont \u00e9t\u00e9 per\u00e7us d\u00e9but septembre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Comme annonc\u00e9 pr\u00e9c\u00e9demment, GenSight Biologics publiera ses comptes semestriels 2026, le 29 septembre apr\u00e8s la cl\u00f4ture des march\u00e9s. La \u00ab&nbsp;Quiet period&nbsp;\u00bb li\u00e9e \u00e0 la publication des r\u00e9sultats financiers d\u00e9butera le 15 septembre 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 8 septembre 2026, 7h30 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui un point sur son activit\u00e9 au cours de l\u2019\u00e9t\u00e9 2026 et [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[98],"class_list":["post-9718","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","post-year-98"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 8 septembre 2026, 7h30 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui un point sur son activit\u00e9 au cours de l\u2019\u00e9t\u00e9 2026 et [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T14:16:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T16:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"competenow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"competenow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/\"},\"author\":{\"name\":\"competenow\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/412117684a8b361d71ffd90c6df779dc\"},\"headline\":\"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026\",\"datePublished\":\"2026-09-08T14:16:56+00:00\",\"dateModified\":\"2026-10-29T16:45:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/\"},\"wordCount\":474,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/\",\"name\":\"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-09-08T14:16:56+00:00\",\"dateModified\":\"2026-10-29T16:45:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/09\\\/08\\\/gensight-biologics-provides-september-2026-business-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\",\"name\":\"GenSight Biologics\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"width\":696,\"height\":696,\"caption\":\"GenSight Biologics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/8104807?trk=prof-exp-company-name\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/412117684a8b361d71ffd90c6df779dc\",\"name\":\"competenow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g\",\"caption\":\"competenow\"},\"sameAs\":[\"http:\\\/\\\/www.gensight-biologics.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics","og_description":"Paris, France, le 8 septembre 2026, 7h30 CEST \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN&nbsp;: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui un point sur son activit\u00e9 au cours de l\u2019\u00e9t\u00e9 2026 et [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/","og_site_name":"GenSight Biologics","article_published_time":"2026-09-08T14:16:56+00:00","article_modified_time":"2026-10-29T16:45:19+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-1.jpg","type":"image\/jpeg"}],"author":"competenow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"competenow","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/"},"author":{"name":"competenow","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/412117684a8b361d71ffd90c6df779dc"},"headline":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026","datePublished":"2026-09-08T14:16:56+00:00","dateModified":"2026-10-29T16:45:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/"},"wordCount":474,"publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"articleSection":["Communiqu\u00e9 de presse financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/","name":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026 | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-09-08T14:16:56+00:00","dateModified":"2026-10-29T16:45:19+00:00","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/09\/08\/gensight-biologics-provides-september-2026-business-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics fait un point sur son activit\u00e9 en septembre 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization","name":"GenSight Biologics","url":"https:\/\/www.gensight-biologics.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","width":696,"height":696,"caption":"GenSight Biologics"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/8104807?trk=prof-exp-company-name"]},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/412117684a8b361d71ffd90c6df779dc","name":"competenow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7e3ca138f7f44e8f5797b5e9219209710e9697048985d96e2ba44cef1929b78f?s=96&d=mm&r=g","caption":"competenow"},"sameAs":["http:\/\/www.gensight-biologics.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=9718"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9718\/revisions"}],"predecessor-version":[{"id":9949,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/9718\/revisions\/9949"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=9718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=9718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=9718"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=9718"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=9718"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=9718"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=9718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}